Veyo brings next-generation technology to healthcare transportation

Veyo, an Arizona-based healthcare transportation company, has developed a method of bringing medical transportation to patients by achieving an on-time trip performance rating of 99.5 percent.

Expectations have increased in recent years for efficiency and quality of ground transportation for consumers as they get access to higher quality, more responsive, cheaper and transparent service from technology and app-based companies. Veyo integrates technologies with needs specific to non-emergency medical transportation (NEMT), including Health Insurance Portability and Accountability Act (HIPAA) compliance, insurance benefit management and eligibility, rural and statewide services, healthcare reporting, pre-scheduled service, fraud monitoring and more.

With the use of supply management, predictive analytics and automated dispatching, and customer-focused tools, Veyo’s model leverages its virtual fleet of independent drivers with commercial providers to improve the matching of supply with demand. Using real-time data and analytics, delays caused by major traffic events or weather are automatically identified and corrected by Veyo before impacting a member as well as catering to each person’s transportation needs and technology comfort level (phone, website, app).

Since being launched in November 2015, Veyo has completed more than one million trips, averaging 10,000 trips per day. Veyo has generated over $100 million in total sales to-date.

In addition to Arizona and the company’s California headquarters, Veyo provides NEMT services in Colorado and Texas, and will serve all Medicaid-eligible participants in Idaho beginning July 2016. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Trimed Popup
Trimed Popup